Secondary polycythaemia with elevated carbon monoxide levels due to hookah pipe smoking: A public health concern

T Moodley, MB ChB, DTM&H; K T Mannaru, MB ChB, MMed (Haem), FC Path (SA) Haem; A Hugo, MB BCh; J A Lines, MB ChB; J M van der Merwe, MB ChB; N Ramparsad, MB BCh, MMed (Haem); N S Holland, MB BCh, FC Path (SA) Haem

Haematology Department, Lancet Laboratories, Johannesburg, South Africa

Corresponding author: T Moodley (trishamoodley@yahoo.com)

Hookah pipe (HP) smoking, also known as hubble bubbly, waterpipe, shisha and narghile, has become a popular way of smoking tobacco over the past decade.[1] HP smoking was previously limited to older males in the Middle East, but has emerged as a trendy practice among youth all over the world, including South Africa (SA).[3] A recent cross-sectional study in Johannesburg, SA, showed that ~26% of grade 8 and 70% of grade 12 learners have smoked an HP.[4] The current widespread use is attributable to lack of knowledge about the dangers of HP smoking, the popular café culture, and the availability of attractive flavours.[3]

Surveys suggest that many people perceive HP smoking as less harmful and less addictive than cigarette smoking, but this is not supported by the literature.[4] Misperceptions include that inhaled smoke has been 'detoxified' by the 'filtering' effects of the water and that smoke from an HP contains less nicotine. There is also a lack of information in the media regarding the health impact of recreational habits, and their intersection with new social norms in the COVID-era, requires critical review. We describe a case series of young HP smokers presenting with secondary polycythaemia with significant clinical sequelae necessitating extensive work-up. HP smoking may lead to acute and chronic carbon monoxide intoxication, with resultant secondary polycythaemia and complications including provoked thrombosis.

All the patients were male, with ages ranging from 28 to 47 years. Five of the patients presented with nonspecific symptoms and polycythaemia as an incidental finding. Two of the patients experienced thromboembolic event.

Laboratory investigations (Table 2) revealed an elevated red cell count and haemoglobin and haematocrit concentrations in all 7 patients, but elevated in only 1 patient. The others were all in normal range.

Bone marrow investigations for polycythaemia, in whom chronic HP smoking was identified as the underlying cause. These patients represent an unusual secondary polycythaemia cohort in that they were young and a subpopulation had documented venous thromboembolism (VTE). The findings highlight some of the potential risks of HP smoking and the need to elicit a full smoking history.[11]
Table 1. Patient clinical information

| Variables                        | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
|----------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Age (years)                      | 28        | 29        | 29        | 47        | 28        | 31        | 34        |
| Sex                              | M         | M         | M         | M         | M         | M         | M         |
| Clinical presentation            | Fever for 3 days, pulmonary emboli | Lethargy, progressive polycythaemia | Pruritus, chronic urticaria | DVT left calf | Haematuria | Pica, restless legs | Headache, fatigue |
| HP smoking history               | Frequency | Daily     | Daily 2 - 3 ×/day | Daily 2 - 3 ×/day | Daily 2 ×/day | Daily 2 - 3 ×/day | Daily 3 - 5 ×/day |
| Duration/session                | ~45 minutes | ~60 - 90 minutes | ~35 minutes | ~60 minutes | ~15 minutes | ~30 - 45 minutes | ~180 minutes per day |
| History of HP smoking            | >10 years | >5 years  | >12 years | 12 months | >11 years | 3 months | 3 years, stopped 2 months before hospital admission |
| Cigarette smoking               | None      | Not known | Not known | None      | 2 years, stopped 10 years ago | 18 years, stopped 2 months before hospital admission | None |
| HP pack-year calculation[^2][^3][^4] | ~56 cigarettes per 45-minute session | ~75 cigarettes per 60-minute session | ~44 cigarettes per 35-minute session | ~75 cigarettes per 60-minute session | 19 cigarettes per 15-minute session | 56 cigarettes per 45-minute session | ~225 cigarettes per 3-hour session |
|                                  | 28 cigarette pack-year equivalent | 19 cigarette pack-year equivalent | 26 cigarette pack-year equivalent | 4 cigarette pack-year equivalent | 10 cigarette pack-year equivalent | 34 cigarette pack-year equivalent |

[^2]: Calculation method.
[^3]: HP = hookah pipe.
[^4]: M = male; DVT = deep-vein thrombosis.

Table 2. Laboratory investigations

| Variables (reference ranges)     | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
|----------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| FBC                              |           |           |           |           |           |           |           |
| RCC (4.5 - 6.5 × 10[^12]/L)      | 6.80      | 6.28      | 7.33      | 7.46      | 6.22      | 6.25      | 6.73      |
| Hb (13.8 - 18.8 g/dL)            | 20.5      | 18.9      | 20.9      | 21.5      | 22.0      | 19.4      | 22.2      |
| Hct (0.40 - 0.56 L/L)            | 0.60      | 0.53      | 0.62      | 0.65      | 0.60      | 0.55      | 0.61      |
| MCV (79 - 100 fL)                | 88        | 84.2      | 84.3      | 86.6      | 95        | 87.5      | 90        |
| WCC (4.0 - 12.0 × 10[^9]/L)      | 2.34      | 6.44      | 10.15     | 6.45      | 5.0       | 7.09      | 4.22      |
| Platelet count (150 - 450 × 10[^9]/L) | 120      | 227      | 263      | 169      | 210      | 260      | 206      |
| BG and COHb (%)*                 | Not performed on hospital admission | COHb-BG instrument unable to calculate parameter (see ‘Discussion’) | Not performed on hospital admission | Not performed on hospital admission | COHb 36.8 | First: BG normal with no COHb measured | COHb 3.8 |
| Serum ferritin (20 - 300 ng/mL)  | Not done  | 207       | 112       | Not done  | 145       | 18        | 599       |
| Erythropoietin (4.3 - 29 mIU/mL) | 4.6       | 8.2       | 22        | Not done  | 3.3       | 11.4      | 13.7      |

[^1]: FBC = full blood count; RCC = red cell count; Hb = haemoglobin; Hct = haematocrit; MCV = mean cell volume; WCC = white cell count; BG = blood gas; COHb = carboxyhaemoglobin; HP = hookah pipe.
[^2]: Reference range for COHb: non-smokers 0.5 - 1.5%; smokers 1 - 2 packs/day 4.0 - 8.0%, >2 packs/day 8.0 - 9.0%; toxic >20%, lethal >50%.
Radiological investigations (Table 3) confirmed the thromboembolic events in 2 patients (patients 1 and 5). The chest radiographs performed indicated normal lung features in 2 of the patients, and showed hyperinflation with prominent hilar pulmonary vessels in 1 patient.

No causes of secondary polycythaemia other than HP smoking were identified.

Discussion
The patients in this series illustrate the potential adverse effects of HP smoking, which include acute carbon monoxide intoxication, thromboembolic events, and secondary polycythaemia.

Carbon monoxide toxicity
The secondary polycythaemia caused by HP smoking develops as a result of tissue hypoxia from chronic exposure to elevated levels of carbon monoxide (CO). CO is a product of the ignited charcoal used to heat the tobacco in the water pipe, and studies have shown plasma levels of carboxyhaemoglobin to be 10 times higher than those observed in cigarette smokers.

Acute CO intoxication is also a possibility. This is associated with a left shift of the oxygen-dissociation curve due to hypoxia. The elevated CO levels cause mitochondrial dysfunction at a cellular level, resulting in myocardial and neuronal necrosis. This process explains the acute cardiac and neurological symptoms that patients develop. Symptoms and signs can be nonspecific and include loss of consciousness and confusion, headache, malaise and nausea. Severe cases may result in seizures, coma, acute myocardial ischaemia and ventricular arrhythmias.

The carboxyhaemoglobin levels measured in our case series were quantified on a point-of-care instrument available at Lancet Laboratories, using a lithium heparinised whole-blood sample transported on ice to the laboratory. The carboxyhaemoglobin level is a calculated parameter, calibrated on the point-of-care instrument, and is part of the co-oximetry function of the blood gas instrument. Availability of this function should be confirmed with the laboratory used. Co-oximetry evaluates the total haemoglobin and determines the percentage of functional (e.g. oxyhaemoglobin) and dysfunctional haemoglobin species such as carboxyhaemoglobin and methaemoglobin. Heparinised syringes and blood tubes can be used for blood gas and carboxyhaemoglobin analysis using small volumes (microlitres) of arterial, venous or capillary blood, but are subject to pre-analytical and analytical variables. These blood samples are stable at room temperature for up to a month at 22°C and refrigerated for several years at 4°C.

Thromboembolic risk
Although our cohort is small, 2 of our patients (28%) presented with a VTE (pulmonary emboli and lower-limb deep-vein thrombosis). Secondary polycythaemia from any cause has been associated with an increased risk of thrombosis. In addition, acute exposure to HP smoke in animal models demonstrated platelet activation and thrombogenesis.

Secondary polycythaemia
Erythrocytosis results in increased blood viscosity. Symptoms of hyperviscosity include headaches, visual disturbances, dyspnoea, abnormal bleeding and severe neurological fall-out such as seizures and coma. These symptoms are alleviated by therapeutic venesection.

Other adverse effects
Non-haematological effects associated with HP smoking include nicotine addiction; exposure to other carcinogens; infection risk (e.g. SARS-CoV-2, herpesvirus, Epstein-Barr virus) by means of a shared mouthpiece, as well as the water in the bowl of the HP apparatus acting as a reservoir for bacterial, mycobacterial and fungal growth; oral and gastrointestinal sequelae such as periodontal disease and oesophageal reflux disease; and cardiovascular and/or cardiopulmonary changes akin to those described with cigarette smoking. Effects in pregnancy have been documented to increase the risk of intrauterine growth restriction and preterm labour.

The perceived harmlessness of HP smoking has resulted in children, adolescents and young adults of all socioeconomic backgrounds increasingly adopting this dangerous but seemingly socially acceptable practice. In view of these misconceptions, there is a need for increased public awareness and education on the adverse effects of HP smoking to prevent an additional burden on our already pressured healthcare system.
Teaching points

- HP tobacco products do not appear to be under the same regulatory scrutiny as traditional tobacco products, which requires review.
- HP-related polycythaemia should be considered in the younger patient with nonspecific symptoms.
- Recreational history is important. Smoking is no longer limited to cigarettes, and a full smoking history should include HP smoking.
- A calculator for HP pack-year history is available online.\(^\text{[2,3]}\)
- In the event of a thromboembolic presentation, exclusion of polycythaemia is recommended in addition to eliciting the patient history.
- A formal carboxyhaemoglobin measurement, or blood gas co-oximetry that is quality controlled, is recommended in the evaluation of polycythaemia, together with the patient history.

Declaration. None.

Acknowledgements. We thank the following doctors for their contribution to the write-up of the case series: Dr Lucille Singh, Dr Mohammed Arbee, Dr Adnaan Variaiva, Dr Lebogang Moja, Dr Robin C Ballantine and Dr Khethiwe Nyuswa, as well as our colleagues Dr Peter Tsagagane and Dr Ryan Benjamin from the Chemical Pathology Department at Lancet Laboratories for their knowledgeable recommendations.

Author contributions. Case series conceptualised by KTM, TM, AH, JAL, JMdVM. Data analysis: TM, AH, JAL, JMdVM. Writing, review and editing: TM, AH, JAL, JMdVM, KTM, NR, NSH. All the authors read and approved the manuscript.

Funding. None.

Conflicts of interest. None.

Accepted 21 June 2021.